Present position: Research Director, Molecular Radiopharmacy, INRASTES, NCSR «Demokritos».
Previous Studies and Experience:
Research Activities:
In his present position and for more than 20 years now, Dr. Nock guides research activities aiming at the design and labeling of a wide spectrum of peptide ligands with medically relevant radiometals, for SPECT (Tc-99m, In-111) and PET (Ga-68) imaging and for radionuclide therapy (Lu-177). He has also coordinated work pertaining to their radiochemical analysis for subsequent use in preclinical and clinical studies for application in the diagnosis and therapy of human tumours. He has been actively involved in the implementation of national and European scientific projects and research networks related to novel radiolabeled vectors. He is responsible for MS and PhD students completing their Thesis on related topics.
His innovative idea on the stabilization of biodegradable radiopeptides by administration of key-protease inhibitors eventually led to the prestigious “Marie Curie Award” (https://www.eanm.org/congresses-events/awards-grants/winners/) offered to the Molecular Radiopharmacy team in October 2013. The innovative and smart design of numerous GPCR-targeting radioligands, subsequently tested by the team, has attracted the attention of the private sector, supporting further clinical radioligand validation and filing of patents. In addition, Dr. Nock is (co)author of numerous peer-reviewed articles and book chapters (>150) as well as congress presentations (>300).
Link to Scopus:
Patents:
The research project “Radiolabeled Vectors in Nuclear Oncology” coded Ε12224 with a 5-year duration (2018-2023) is coordinated by Dr. T. Maina-Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with Cyclotron Rotterdam BV, Erasmus, MC, Rotterdam, The Netherlands. The latter...
The research project “New SST2R-antagonists in the diagnosis of neuroendocrine tumors with PET/CT” coded Ε12452 with a 1-year duration (2020-2022) is coordinated by Dr. T. Maina-Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Department of Chemistry, ...
The research project “Development of Radiometalated GRPR-Antagonists for Tumor Diagnosis and Therapy” coded Ε11902 with a 3-year duration (2014-2016) is coordinated by Dr. T. Maina-Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Nuclear Medicine & Radiology ...
The research project “Improved Tumor Targeting with Radiolabeled Peptidomimetics” with a 5-year duration (2018-2023) is coordinated by Dr. B. A. Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Ludwig Boltzmann Institute Applied Diagnostics, sponsored by Austrian...
The research project “Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma” coded ERANET TRANSCAN-GRAN-T-MTC (Ε11820) with a 3-year duration (20...
The research project “(Radio)diagnostic - (Radio)therapeutic Peptides and Peptide-like Molecules for Use in Oncology” coded Ε11461 with a 7-year duration (2007-2014) is coordinated by B. A. Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Department of Nuclear Me...
